Researchers at the Wuhan Institute of Virology have identified a new coronavirus, HKU5-CoV-2, which has the potential to enter human cells similarly to SARS-CoV-2, the virus responsible for COVID-19. However, experts caution that HKU5-CoV-2 does not bind to human cells as effectively and is less adept at causing infections. The findings were published in the journal Cell, where scientists utilized test tubes and models of human biological systems to study the virus's transmission potential.
HKU5-CoV-2, found in bats, belongs to a larger family of coronaviruses. While some coronaviruses can lead to mild illness in humans, others can result in severe disease. The study indicated that the spike protein of HKU5-CoV-2 can attach to a receptor enzyme on human cells, aided by a feature known as a "furin cleavage site." This mechanism is reminiscent of how SARS-CoV-2 operates.
Despite these similarities, the researchers emphasized that the risk of HKU5-CoV-2 emerging in human populations should not be exaggerated. Dr. Michael Osterholm, an infectious disease expert, described the public response to the research as potentially "overblown." He suggested that existing immunity to similar viruses could provide some level of protection against future outbreaks.
In the wake of this research, shares in COVID-19 vaccine manufacturers, including Pfizer, Moderna, and Novavax, experienced a rise, indicating market sensitivity to developments in viral research. Should HKU5-CoV-2 infect humans, the study suggested that treatments such as monoclonal antibodies and antiviral drugs may be effective in managing the infection. These treatments are designed to inhibit viral spread and alleviate symptoms, building on prior advancements made during the COVID-19 pandemic.